A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Clinical trial NCT05544929 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05544929
Sponsor: Novartis Pharmaceuticals
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Carcinoma, Non-Small-Cell Lung Cutaneous Melanoma Carcinoma, Renal Cell Carcinoma, Ovarian Epithelial Nasopharyngeal Carcinoma Carcinoma, Thymic Anal Cancer Mesothelioma Esophagogastric Cancer High Microsatellite Instability Colorectal Carcinoma Squamous Cell Carcinoma of Head and Neck Triple Negative Breast Neoplasms

Start date: 2022-10-26
Primary completion: 2027-09-01
Enrollment: 126

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.